UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 26, 2009
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On March
25, 2009, Oramed Pharmaceuticals Inc. (the “Company”) issued a press release
announcing that it has been selected to present Oral Insulin Phase 2A trial
results at the upcoming annual meeting of the ADA on June 5 through 9, 2009, in
New Orleans.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated herein by reference.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
99.1
|
Press
Release dated March 25, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| ORAMED PHARMACEUTICALS INC. | |||
|
Dated:
March 26, 2009
|
By:
|
/s/ Nadav Kidron | |
| Nadav Kidron | |||
| President, CEO and Director | |||
Oramed Pharmaceuticals to Present
Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA
(June 5-9, New Orleans, LA)
JERUSALEM,
Israel – March 25, 2009 – Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a
developer of oral delivery systems, announced today that it has been selected to
present the results from the study, entitled, “Open Label Study to Assess the
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin
Formulations in Subjects with Type 2 Diabetes (T2DM)” at the upcoming
69th
Annual American Diabetes Association’s Scientific Sessions Conference in New
Orleans. The presentation will highlight the successful results from
its oral insulin trials on type 2 diabetes patients completed in August
2008.
An
abstract will also be printed in the Scientific Sessions Abstract Book, the June
2009 supplement to the journal Diabetes.
“Oramed
is pleased to present this poster featuring the results from our phase 2A study
of ORMD-0801 on type 2 diabetes patients and to share the information with our
colleagues,” said Nadav Kidron, Oramed CEO. “As we indicated at the
completion of the study, the trial demonstrated that the oral insulin capsule
had a good safety profile and was well tolerated and effective in lowering blood
glucose levels in patients with type 2 diabetes.”
Oramed’s
poster has been assigned presentation number 434-P Clinical Therapeutics/New
Technology - Insulin Delivery Systems and is available for viewing throughout
the conference. A representative of the company will be available to
answer questions on Monday, June 8 from 12-2 PM at the Morial Convention
Center.
For more
information about the ADA and the upcoming conference, please visit
http://professional.diabetes.org
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relation Contacts:
Oramed
Pharmaceuticals
Tara
Horn
USA: +1
646 240 4193
Int’l:: +
972-54-334-318
Office: +
972-2-566-0001
Email: Tara@oramed.com